logo
Plus   Neg
Share
Email

Amgen To Acquire 20.5% Stake In BeiGene For Approx. $2.7 Bln - Quick Facts

Amgen (AMGN) has entered into a strategic collaboration with BeiGene that will accelerate Amgen's plans to expand its oncology presence in China. BeiGene is a research-based, oncology-focused biotechnology company. Amgen will acquire a 20.5 percent stake in BeiGene for approximately $2.7 billion. This represents a purchase price of $174.85 per BeiGene American Depositary Share on NASDAQ.

Amgen and BeiGene will collaborate to advance 20 medicines from Amgen's oncology pipeline in China and globally. BeiGene will share global research and development costs and contribute up to $1.25 billion. Amgen will pay royalties to BeiGene on the sales of these products outside of China.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Procter & Gamble Company (PG) reported that its second-quarter core earnings per share rose 14 percent year-on-year, due to lower non-core restructuring charges versus the prior year. Currency-neutral core earnings per share increased 15 percent. Organic sales were up five percent, for the quarter.... While reporting financial results for the fourth quarter on Thursday, JetBlue Airways Corp. (JBLU) provided its financial outlook for the first quarter and the full-year 2020. For the first quarter, the company expects earnings in a range of $0.10 to $0.20 per share. Capacity is expected to increase... Five Star Food Inc. is recalling certain Sham Gardens Excellent tahina containers for potential contamination with Salmonella, the US Food and Drug Administration said in a statement. The recall involves 100 cases of Excellent tahina 800 g and 100 cases of Excellent tahina 400 g containers. The Garden City, Michigan-based company, however, has not received any reports of illness.
Follow RTT
>